Influenza A / B influenza virus antigen detection kit (fluorescence immunochroma
Influenza A / B influenza virus antigen detection kit (fluorescence immunochromatography)

Influenza A / B influenza virus antigen dΩ'etection kit (fluorescence immuno"★chromatography)

Clinical background

   The epidemic ∞☆ ‌of influenza (flu) is ® ∞seasonal and highly contagious, which can​‍ easily cause widespread epi≠≈demics. In the 20th century, three ★§influenza pandemics occurred in£←¥× the world, namely the "Spanish f∞$✔•lu" caused by H1N1 virus i‍γδn 1918, the "Asian fl£‌u" caused by H2N2 virus in 1™←957, and the "Hong Kong flu" caused by H3N2φ∏ virus in 1968. In recent years,≤¥ the flu situation is still very serious. T Ωhe infection rate in the severe influenz®↓∏&a season from 2017 to 2018 reac'"hed 7.1%. This data reached a new high γδ≠☆since 2009. During this period, most©β & hospitals were overcrowded and the s→'ituation was grim.
 
  In response to the serio×÷'✘usness of influenza's α threat to humans, based on the fluoresce→Ωnt nanomicrosphere technology platf≤★Ω↔orm, our company has broken through tλ♠"he limitations of the low sensitiv↔¶σity of the colloidal Ω™✘gold method and the slow d ✔φetection of PCR nucleic acid methods comγφmonly used in the marke©₹≠φt, becoming a new generation of detection t ÷↔λechnology.


First in China

★ National High-tech Research a‍₹¶nd Development Plan (863 Plan)
★ Shenzhen's major strategic technology ±≠research products
★ With Tsinghua University a$<s the leader, compre₽Ω♠πhensively develop products   €for production, study‍₩, research and application
★ Sensitivity is 10-10®λ0 times higher than traditio‌&¥nal colloidal gold metho₹←₩ d
★ Compared with PCR detection met ≠​♠hod, the coincidence ra¶ > te is up to 80%
★ On-site inspection, results☆>> in 15 minutes


Technical principle (fl≥δuorescence immunochromatography)


  The samples were added dropwise ≈λ✘to the two wells of the test cards A and B. Afφ&→∏ter the influenza A and (or) influenza ★ B virus antigens were co₽→mbined with the fluore©•<scent microsphere-labeled influenza A and (o¥∑≥'r) influenza B virus nucleoprotein monocl☆δλΩonal antibodies After the chromatλ‌ography to the test line is capt  ured by the coated antibody, under the 365φ™φβnm wavelength ultravi★↕★olet radiation, a fluorescent band ap≠♥pears, and the influenza A and / or B viruses c $☆an be determined by naked eyes.


Product advantages
The first in China : the first influenza virus det¥βection product developed based on fluoresc€↔€ent nanotechnology, the technology is nationall​©§ y leading and
Convenient : it can be used for on< -site testing, which is convenient for emerge↑♣ncy, outpatient, community hosε ★​pitals and basic hospitals to♦≤ develop
Quickly : a single sample can be completed in 15 minutes
High  sensitivity : 10-100 times higher sensitivity than colloidal g&∏↕old detection technology,
Strong specificity : no cross-reaction with other respiratory patho$≠≈✘gens and other subtypes,
Good stability : intra-batch difference and inter-b♠βδatch difference <5%

Comparison of clinical methodologies

Detection method

Advantage

limitation

application

PCR detection

High sensitivity and ac  πcuracy

Need special laboratory  ​≈and 

equipment to carry out, 

an experiment process takes 

3-4 hours, high testing α₩£cost

Specific patients and 

specific departments

Colloidal gold

Fast, results in 15 mi ✔ &nutes

Sensitivity accuracy is →>limited 

by the technology platf ↕orm, 

low sensitivity, low accuracy, 

high false negative

Preliminary clinical screen±¥ing, 

as well as the development of 

basic hospitals

Virus culture

High accuracy

Long time required, ™αup to 

6-7 days

Specialized laboratory ∑✔☆diagnosis

This product
(Fluorescent 

Nanotechnology)

Fast, easy to operate, the results 

are produced within 15 minutes, 

high sensitivity and accuracy, and up to€× 

80% consistency with PCR c​​φ↑ontrol

Low limitations, no specia↓✘δ§l 

laboratories and equipment 

required

Preliminary clinical scre♥ε®ening, 

and the development of 

grassroots hospitals

The need for rapid testing

01. Flu symptoms are generally only fever, body pain‌ ∑, significant fatigue, and mild respiratory‌© symptoms, requiring timely€δ≈ treatment, otherwise♠‍≥ it is easy to induce other chronic diseases;
02. Most of them can heal without treatment, b£≥ut for infants and young children ↔→♠with poor resistance, theββ↔ elderly and patients with cardiopulmonary d↕'®±iseases, they are prone to death due to serio ✘φus complications such as pneumonia
03. Sudden onset and extremely infectious. If¥× ∏ the patient does not pay$♠ attention to isolation, it is easy to in±↓fect people around them;
04. According to the mecha←<σ nism of influenza disease, patie ±nts use drugs within 24 hours for b©<est results;
05. Accurate diagnosis to avoid the abuse of♣Ω←γ antibiotics.

Application field
 Clinical, hot clinic, emergenc≈♦♥y test
 Infection sentinel surveillance of•≠•♠ disease control system, ra↓≠¥©pid screening of epidemic s""™‌cene
 Influenza A / B∞↕σ screening
 Risk assessment of influ÷≠₹γenza A / B
 High-risk groups, newbγδorn influenza screening
product information
Test specimen: throat swab
Technical principle: fluorescence immunochromatography
Packing specification: 20 tests/ kit
Validity: 18 months
Applicable instrument: Fluorescence chromatography test ≠$paper interpreter